Olukayode Sosina

This inventor holds 9 USPTO granted patents and 9 published patent applications. Top assignees: Regeneron Pharmaceuticals, Inc., Mcgill University. Active years: 2022-2026.

USPTO Granted Patents = 9 (Patent Applications = 9)

% Patents Active = 100.0

Average Co-Inventor Count = 5.7

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

9 out of 1,479

Regeneron Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2022-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698530 - Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors (2026-08-04),

2. 12234460 - Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors (2025-02-25),

3. 12123001 - Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors (2024-10-22),

4. 12018259 - Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors (2024-06-25),

5. 11957704 - Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors (2024-04-16),

6. 11891607 - Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors (2024-02-06),

7. 11773393 - Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors (2023-10-03),

8. 11759476 - Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors (2023-09-19),

9. 11359246 - Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors (2022-06-14),

Title: The Innovative Contributions of Olukayode Sosina

Introduction

Olukayode Sosina is a notable inventor based in Tarrytown, NY (US). He has made significant contributions to the field of medical treatments, holding a total of 9 patents. His work focuses on innovative methods that address critical health issues, particularly in bone mineral density and liver diseases.

Latest Patents

Among his latest patents, Sosina has developed methods for treating decreased bone mineral density using cluster of differentiation 109 (CD109) inhibitors. This patent outlines techniques for identifying subjects at risk of developing decreased bone mineral density and offers potential therapeutic approaches. Additionally, he has patented methods for treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors. This work provides valuable insights into treating individuals with liver diseases or type 2 diabetes, along with methods for identifying those at increased risk.

Career Highlights

Sosina has worked with prominent organizations, including Regeneron Pharmaceuticals, Inc. and the Royal Institution for the Advancement of Learning/McGill University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Sosina has collaborated with notable colleagues such as Luca Andrea Lotta and Aris I Baras. These partnerships have further enhanced his research and innovation capabilities.

Conclusion

Olukayode Sosina's contributions to medical science through his patents and collaborations highlight his commitment to improving health outcomes. His innovative methods continue to pave the way for advancements in treatment options for critical health conditions.